Key publications

12.012023
Predicted effects of the introduction of long acting injectable cabotegravir pre exposure prophylaxis in sub Saharan Africa a modelling study
Smith J, Bansi-Matharu L, Cambiano V, Dimitrov D, Bershteyn A, van de Vijver D, Kripke K, Revill P, Boily MC, Meyer-Rath G, Taramusi I, Lundgren JD, van Oosterhout JJ, Kuritzkes D, Schaefer R, Siedner MJ, Schapiro J, Delany-Moretlwe S, Landovitz RJ, Flexner C, Jordan M, Venter F, Radebe M, Ripin D, Jenkins S, Resar D, Amole C, Shahmanesh M, Gupta RK, Raizes E, Johnson C, Inzaule S, Shafer R, Warren M, Stansfield S, Paredes R, Phillips AN; HIV Modelling Consortium
READ
08.022023
Characteristics and short and long term direct medical costs among adults with timely and delayed presentation for HIV care in the Netherlands
Popping S, Versteegh L, Nichols BE, van de Vijver DAMC, van Sighem A, Reiss P, Geerlings S, Boucher CAB, Verbon A; ATHENA observational cohort
READ
15.022023
Investigational drugs for HIV trends opportunities and key players
Overmars RJ, Krullaars Z, Mesplède T.
READ
03.042022
Dolutegravir Monotherapy as Maintenance Strategy A Meta Analysis of Individual Participant Data From Randomized Controlled Trials
Fournier AL, Hocqueloux L, Braun DL, Metzner KJ, Kouyos RD, Raffi F, Briant AR, Martinez E, De Lazzari E, Negredo E, Rijnders B, Rokx C, Günthard HF, Parienti JJ.
READ
13.052022
Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war struck Ukraine
Vasylyev M, Skrzat-Klapaczyńska A, Bernardino JI, Săndulescu O, Gilles C, Libois A, Curran A, Spinner CD, Rowley D, Bickel M, Aichelburg MC, Nozza S, Wensing A, Barber TJ, Waters L, Jordans C, Bramer W, Lakatos B, Tovba L, Koval T, Kyrychenko T, Dumchev K, Buhiichyk V, Smyrnov P, Antoniak S, Antoniak S, Vasylyeva TI, Mazhnaya A, Kowalska J, Bhagani S, Rokx C; European AIDS Clinical Society (EACS) Young Investigators (YING)
READ
02.012022
Evaluation of HIV 1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy treated individuals
Moldt B, Günthard HF, Workowski KA, Little SJ, Eron JJ, Overton ET, Lehmann C, Rokx C, Kozal MJ, Gandhi RT, Braun DL, Parvangada A, Li J, Martin R, Selzer L, Cox S, Margot N, Liu H, Slamowitz D, Makadzange T, Collins SE, Geleziunas R, Callebaut C.
READ
22.062022
Catchet MS identifies IKZF1 targeting thalidomide analogues as novel HIV 1 latency reversal agents
Enrico Ne, Raquel Crespo, Ray Izquierdo-Lara, Shringar Rao, Selin Koçer, Alicja Górska, Thomas van Staveren, Tsung Wai Kan, David van de Vijver, Dick Dekkers, Casper Rokx, Panagiotis Moulos, Pantelis Hatzis, Robert-Jan Palstra, Jeroen Demmers, Tokameh Mahmoudi
READ
05.112022
HIV 1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence a case report

van Kampen J, Pham HT, Yoo S, Overmars RJ, Lungu C, Mahmud R, Schurink CAM, van Boheemen SGruters RAFraaij PLA, Burger DMVoermans JJC, Rokx C, van de Vijver DAMC, Mesplède T 

READ
01.202021
A two color haploid genetic screen identifies novel host factors involved in HIV latency

Michael D Röling, Mahsa Mollapour Sisakht, Enrico Ne, Panagiotis Moulos, Mateusz Stoszko, Elisa De Crignis, Helen Bodmer, Tsung Wai Kan, Maryam Akbarzadeh, Vaggelis Harokopos, Pantelis Hatzis, Robert-Jan Palstra, Tokameh Mahmoudi.

READ
04.302021
Selective cell death in HIV 1 infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir

Rao S, Lungu C, Crespo R, Steijaert TH, Gorska A, Palstra RJ, Prins HAB, van Ijcken W, Mueller YM, van Kampen JJA, Verbon A, Katsikis PD, Boucher CAB, Rokx C, Gruters RA, Mahmoudi T. Nature Communications.

READ
05.232021
Launching a multidisciplinary European collaboration towards a cure for HIV The EU2Cure Consortium
C Rokx, H A B Prins, L Vandekerckhove, S J Fidler, J Frater, M Bracchi, O S Søgaard, M Tolstrop, T A Rasmussen, M Salgado, J Blanco, J Martinez-Picado, B Clotet, G Tambussi, A Groenendijk, A Verbon, C A B Boucher. J Virus Erad
READ
04.302021
Induction of selective cell death in HIV 1 infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir
Rao, S., Lungu, C., Crespo, R., Steijaart, T.H., Gorska A, Palstra, R.J., Prins, H.A.B., van IJcken, W., Mueller, Y.M., van Kampen, J.J.A., Verbon, A., Katsikis, P.D., Boucher, C.A.B., Rokx, C., Gruters, R.A. and Mahmoudi, T.
READ
11.292021
Cohort profile the Netherlands Cohort Study on Acute HIV infection NOVA a prospective cohort study of people with acute or early HIV infection who immediately initiate HIV treatment
Dijkstra M, Prins H, Prins JM, Reiss P, Boucher C, Verbon A, Rokx C, de Bree G.BMJ
READ
11.182021
Towards zero new HIV infections in the Netherlands proactive testing in case of indicator conditions
Bogers SJ, Jordans CCE, Rokx C.
READ
07.192021
Quality of life among people living with HIV in England and the Netherlands: a population-based study
Popping S, Kall M, Nichols BE, Stempher E, Versteegh L, van de Vijver DAMC, van Sighem A, Versteegh M, Boucher C, Delpech V, Verbon A.
READ
04.302021
Selective cell death in HIV 1 infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir
Shringar Rao, Cynthia Lungu, Raquel Crespo, Thijs H. Steijaert, Alicja Gorska, Robert-Jan Palstra, Henrieke A. B. Prins, Wilfred van Ijcken, Yvonne M. Mueller, Jeroen J. A. van Kampen, Annelies Verbon, Peter D. Katsikis, Charles A. B. Boucher, Casper Rokx, Rob A. Gruters & Tokameh Mahmoudi 
READ
09.022020
Inter Laboratory Reproducibility of Inducible HIV 1 Reservoir Quantification by TILDA
Lungu C, Procopio FA, Overmars RJ, Beerkens RJJ, Voermans JJC, Rao S, Prins HAB, Rokx C, Pantaleo G, Vijver DAMCV, Mahmoudi T, Boucher CAB, Gruters RA, Kampen JJAV.
READ
08.122020
Gliotoxin identified from a screen of fungal metabolites disrupts 7SK snRNP releases P TEFb and reverses HIV 1 latency

Stoszko M, Al-Hatmi AMS, Skriba A, Roling M, Ne E, Crespo R, Mueller YM, Najafzadeh MJ, Kang J, Ptackova R, LeMasters E, Biswas P, Bertoldi A, Kan TW, de Crignis E, Sulc M, Lebbink JHG, Rokx C, Verbon A, van Ijcken W, Katsikis PD, Palstra RJ, Havlicek V, de Hoog S, Mahmoudi T.

READ
08.012020
Towards the next step LoViRet patients for HIV 1 cure studies
Crespo R, Rokx C, Mahmoudi T.
READ
02.012020
Development of C TILDA A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV 1

Bertoldi A, D'Urbano V, Bon I, Verbon A, Rokx C, Boucher C, van Kampen JJA, Gruters RA, Gallinella G, Calza L, Mahmoudi T, De Crignis E, Re MC. J Virol. Methods.

READ
09.132020
Hypothetical questionnaires may overestimate willingness to participate in HIV cure research Comparison of a cross sectional survey to actual willingness to participate in an HIV cure study in the Netherlands
Prins HAB, Paulus MR, Rokx C, Been SK, Verbon A. J
READ
05.142020
Risk of recurrent venous thromboembolism in patients with HIV infection A nationwide cohort study
Rokx C, Borjas Howard JF, Smit C, Wit FW, Pieterman ED, Reiss P, Cannegieter SC, Lijfering WM, Meijer K, Bierman W, Tichelaar V, Rijnders BJA; ATHENA observational HIV cohort
READ
19.032019
Catchet MS identifies IKZF1 targeting Thalidomide analogues as novel HIV 1 latency reversal agents
By: Enrico Ne, Raquel Crespo, Ray Izquierdo-Lara, Shringar Rao, Selin Koçer, Alicja Górska, Thomas van Staveren, Tsung Wai Kan, Dick Dekkers, Casper Rokx, Panagiotis Moulos, Pantelis Hatzis, Robert-Jan Palstra, Jeroen Demmers, Tokameh Mahmoudi
READ
10.012019
A broad drug arsenal to attack a strenuous latent HIV reservoir

Stoszko M, Ne E, Abner E, Mahmoudi T. Curr Opin Virol.

READ
01.012019
T cell toxicity of HIV latency reversing agents
 Zhao M, De Crignis E, Rokx C, Verbon A, van Gelder T, Mahmoudi T, Katsikis PD, Mueller YM.
READ
07.012019
Therapeutic vaccine in chronically HIV 1 infected patients a randomized double blind placebo controlled phase IIa trial with HTI TriMix
De Jong, W., Leal, L., Buyze, J., Pannus, P., Guardo, A.C., Salgado, M., Mothe, B., Molto, J., Moron-Lopez, S., Galvez, C., Florence, E., Vanham, G., van Gorp, E.C.M., Brander, C., Allard, S.D., Thielemans, K., Martinez-Picado, J., Plana, M., Garcia, F. and Gruters, R.A.
READ
12.132019
Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy
Wijting IEA, Wit FWNM, Rokx C, Leyten EMS, Lowe SH, Brinkman K, Bierman WFW, van Kasteren MEE, Postma AM, Bloemen VCM, Bouchtoubi G, Hoepelman AIM, van der Ende ME, Reiss P, Rijnders BJA; ATHENA national observational HIV cohort.
READ
02.152019
Incidence of a first venous thrombotic event in people with HIV in the Netherlands a retrospective cohort study
Howard JFB, Rokx C, Smit C, Wit FWNM, Pieterman ED, Meijer K, Rijnders B, Bierman WFW, Tichelaar YIGV; ATHENA observational HIV cohort investigators.
READ
12.202018
Small Molecule Targeting of Specific BAF mSWISNF Complexes for HIV Latency Reversal
Marian CA, Stoszko M, Wang L, Leighty MW, de Crignis E, Maschinot CA, Gatchalian J, Carter BC, Chowdhury B, Hargreaves DC, Duvall JR, Crabtree GR, Mahmoudi T, Dykhuizen EC.
READ
01.012018
HIV 1 resistance dynamics in patients failing dolutegravir maintenance monotherapy
Wijting, I.E.A., Lungu, C., Rijnders, B.J.A., van der Ende, M.E., Pham, H.T., Mesplede, T., Pas, S.D., Voermans, J.J.C., Schuurman, R., van de Vijver, D.A.M.C., Boers, P.H.M., Gruters, R.A., Boucher, C.A.B., van Kampen, J. J.A.
READ
02.212018
Allele specific long distance regulation dictates IL 32 isoform switching and mediates susceptibility to HIV 1
Palstra RJ, de Crignis E, Röling MD, van Staveren T, Kan TW, van Ijcken W, Mueller YM, Katsikis PD, Mahmoudi T.
READ
04.272018
A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV 1 Reservoir for Reactivation from Other Shock Drugs
Abner E, Stoszko M, Zeng L, Chen HC, Izquierdo-Bouldstridge A, Konuma T, Zorita E, Fanunza E, Zhang Q, Mahmoudi T, Zhou MM, Filion GJ, Jordan A.
READ
01.012018
Phase I clinical trial of an intranodally administered mRNA based therapeutic vaccine against hiv 1 infection
Leal, L., Crespo, A., Morón-López, S., Salgado, M., Mothe, B., Heirman, C., Pannus, P., Vanham, G., van den Ham, H.J., Gruters, R., Andeweg, A., Martínez-Picado, J., van Meirvenne, S., Pich, J., Arnaiz, J.A., Gatell, J.M., Brander, C., Thielemans, K., Plana, M., García, F., on behalf of the iHIVARNA consortium
READ
12.042017
Dolutegravir as maintenance monotherapy for HIV DOMONO a phase 2 randomized non inferiority trial
Wijting I, Rokx C, Boucher C, van Kampen J, Pas, S, de Vries-Sluijs TEMS, Schurink CAM, Bax H, Derksen M, Andrinopoulou ER, van der Ende ME, van Gorp E, Nouwen JL, Verbon A, Bierman W, Rijnders BJA.
READ
10.262017
Dolutegravir as maintenance monotherapy for HIV DOMONO a phase 2 randomised non inferiority trial
Wijting I, Rokx C, Boucher C, van Kampen J, Pas S, de Vries-Sluijs T, Schurink C, Bax H, Derksen M, Andrinopoulou ER, van der Ende M, van Gorp E, Nouwen J, Verbon A, Bierman W, Rijnders B.
READ
07.172017
Unite forces to validate biomarkers in the quest for lasting HIV remission
Rokx C, Vella S, Pantaleo G, Lévy Y, Boucher CA.
READ
02.162016
Dolutegravir as maintenance monotherapy first experiences in HIV 1 patients
Rokx C, Schurink CA, Boucher CA, Rijnders BJ.
READ
05.162016
Global epidemiology of drug resistance after failure of WHO recommended first line regimens for adult HIV 1 infection a multicentre retrospective cohort study
TenoRes Study Group. Lancet Infect Dis.
READ
10.052016
Risk Factors for Non Adherence to cART in Immigrants with HIV Living in the Netherlands Results from the ROtterdam ADherence ROAD Project
Been SK, van de Vijver DA, Nieuwkerk PT, Brito I, Stutterheim SE, Bos AE, Wolfers ME, Pogány K, Verbon A.
READ
11.272015
Small Molecule Inhibitors of BAF A Promising Family of Compounds in HIV 1 Latency Reversal
Stoszko M, De Crignis E, Rokx C, Khalid MM, Lungu C, Palstra RJ, Kan TW, Boucher C, Verbon A, Dykhuizen EC, Mahmoudi T.
READ
07.012015
Second European Round Table on the Future Management of HIV
Rokx C, Richman DD, Müller-Trutwin M, Silvestri G, Lunzen J, Khoo S, Lichterfeld M, Altfeld M, Perno CF, Hunt PW, Mallon P, Rockstroh JK, Pozniak AL, Clotet B, Boucher CA.J
READ
11.212014
HIV eradication combinatorial approaches to activate latent viruses
De Crignis E, Mahmoudi T.
READ
01.012014
Abasic phosphorothioate oligomers inhibit HIV 1 reverse transcription and block viral transmission across ectocervical organ cultures

Fraietta JA, Mueller YM, Lozenski KL, Ratner D, Boesteanu AC, Hancock AS, Lackman-Smith C, Zentner IJ, Chaiken IM, Chung S, LeGrice SFJ, Snyder BA, Mankowski MK, Jones NM, Hope JL, Gupta P, Anderson SH, Wigdahl B, Katsikis PD.

READ
01.012013
Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus HIV infection
. Fraietta JA, Mueller YM, Yang G, Boesteanu AC, Gracias DT, Do DH, Hope JL, Kathuria N, McGettigan SE, Lewis MG, Giavedoni LD, Jacobson JM, Katsikis PD.
READ
07.302012
The BAF complex and HIV latency
Mahmoudi T.
READ
01.012012
A Phase IIIa Immunotherapy Trial of HIV 1 Infected Patients with Tat Rev and Nef expressing Dendritic Cells followed by Treatment Interruption

Allard, S.D., De Keersmaecker, B., de Goede, A.L., Verschuren, E.J., Koetsveld, J., Reedijk, M.L., Wylock, C., De Bel, A.V.,  Vandeloo, A., Pistoor, F., Heirman, C., Beyer, W.E.P., Eilers, P.H.C., Corthals, J., Padmos, I., Thielemans, K., Osterhaus, A.D.M.E, Lacor, P., van der Ende, M.E., Aerts, J.L., van Baalen, C.A., Gruters R.A.

READ
01.012012
Current and future applications of dried blood spots in viral disease management
Snijdewind, I.J.M., van Kampen, J.J.A., Fraaij, P.L.A., Osterhaus, A.D.M.E., van der Ende, M.E., Gruters R.A.
READ
03.272012
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection the randomized Primo SHM trial
Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A, Brinkman K, van der Ende ME, Soetekouw R, de Wolf F, Lange JM, Schuitemaker H, Prins JM; Primo-SHM Study Group.
READ
01.012011
Interleukin 15 delays viral suppression and fails to promote immune reconstitution in virally suppressed chronically SIV infected macaques
Lugli E, Mueller YM, Lewis L, Villinger F, Katsikis PD, Roederer M.
READ
01.012011
The cytokine network of acute HIV infection a promising target for vaccines and therapy to reduce viral set point
Katsikis PD, Mueller YM, Villinger F.
READ
11.092011
Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency
Rafati H, Parra M, Hakre S, Moshkin Y, Verdin E, Mahmoudi T.
READ
01.012011
Biomedical application of MALDI mass spectrometry for small molecule analysis
van Kampen J. J.A., Burgers P. C., de Groot R., Gruters R. A., Luider T. M.
READ
01.012009
Vaccine induced enhancement of viral infections
Huisman W., Martina B.E.E., Rimmelzwaan G.F., Gruters R.A. and Osterhaus A.D.M.E.
READ
01.012008
AIDS Vaccine Research Consider Co Infections
Gruters, R. and Osterhaus A.
READ
04.012007
Effects of active treatment discontinuation in patients with a CD4 T cell nadir greater than 350 cellsmm3 48 week Treatment Interruption in Early Starters Netherlands Study TRIESTAN
Pogány K, van Valkengoed IG, Prins JM, Nieuwkerk PT, van der Ende I, Kauffmann RH, Kroon FP, Verbon A, Nievaard MF, Lange JM, Brinkman K. J Acquir Immune Defic Syndr.
READ
01.012002
Comparison of the efficacy of early versus late viral proteins in vaccination against SIV
Stittelaar K.J., Gruters R.A., Schutten M., van Baalen C.A., van Amerongen G., Cranage M., Liljestrom P., Sutter G. and Osterhaus A.D.M.E
READ
01.011997
Rev and Tat specific cytotoxic T cells inversely correlate with rapid progression to AIDS
Van Baalen, C.A., Pontesilli, O., Huisman, R.C., Miedema, F., Geretti, A.M., Gruters, R.A., and Osterhaus, A.D.M.E.
READ
01.011996
Human Immunodeficiency Virus type 2 in 12 European residents Virus characteristics and disease progression
van der Ende, M.E., Schutten, M., Ly, T.D., Gruters, R.A., and Osterhaus, A.D.M.E.
READ
01.011993
Early replication steps but not cell type specific signalling of the viral long terminal repeat determine HIV 1 monocytotropism
Schuitemaker, H., Groenink, M., Meyaard, L., Kootstra, N.A., Fouchier, R.A.M., Gruters, R.A., Huisman, H.G., Tersmette, M., and Miedema, F.
READ
01.011991
Phenotypic heterogeneity in a panel of infectious molecular immunodeficiency virus type 1 clones derived from a single individual
Groenink, M., Fouchier, R.A.M., De Goede, R.E.Y., De Wolf, F., Gruters, R.A., Cuypers, H.T.M., Huisman, J.G., and Tersmette, M.
READ
01.011990
Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus infected men
Van Noesel, C.J.M., Gruters, R.A., Terpstra, F.G., Schellekens, P.T.A., Van Lier, R.A.W., and Miedema, F.
READ
01.011989
Evidence for a role of virulent human immunodeficiency virus HIV variants in the pathogenesis of acquired immunodeficiency syndrome Studies on sequential HIV isolates
Tersmette, M., Gruters, R.A., De Wolf, F., De Goede, R.E.Y., Lange, J.M.A., Schellekens, P.T.A., Goudsmit, J., Huisman, H.G., and Miedema, F.
READ
01.011988
Differential syncytiuminducing capacity of human immunodeficiency virus isolates Frequent detection of syncytiuminducing isolates in patients with acquired immunodeficiency syndrome AIDS and AIDSrelated complex
Tersmette, M., De Goede, R.E.Y., Al, B.J.M., Winkel, I.N., Gruters, R.A., Cuypers, H.T.M., and Miedema, F.
READ
01.011987
Interference with HIVinduced syncytium formation and viral infectivity by inhibitors of trimming glucosidase
Gruters, R.A., Neefjes, J.J., Tersmette, M., De Goede, R.E.Y., Tulp, A., Huisman, H.G., Miedema, F., and Ploegh, H.L.
READ

Collaborations for EHEG

And countries with ties to EHEG 
Europe
NIH-TRIP partners, European HIV Vaccine Alliance (EHVA) partner, Initiator/coordinator EU2Cure, PIs and WP leaders in NL4Cure
(Eur) Asia
North America
NIH-TRIP partners
South America
NIH-TRIP partners
Africa
Kwazulu Natal; Makere Univ
Australia

Achievements

Casper Rokx
AIDSfonds next gen scientist, Erasmus MC Fellowship,Martijn Verbrugge Award best HIV science 2015
Charles Boucher
Founder of EHEG
Cynthia Lungu
Aidsfonds Small Grant 2020
Henrieke Prins
ECDC fellowship
HIV 1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence a case report

HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report

Katie Hensley
 
Raquel Crespo Galvan
Aidsfonds Small Grant 2020
Shringar Rao
Next gen scientist, Gilead Research Scholar’s programme in HIV
Thibault RVC Mesplède
Telemachus Scholar
CTN/BMS Scholar
Young Investigator Awardee (CAHR, IAS, CROI)
Research Leadership Awardee (LDI)